Advertisement

Malignes Mesotheliom

  • A. Krarup-Hansen
  • H. H. Hansen

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Anderson M, Olsen JH (1985) Trend and distribution of mesothelioma in Denmark. Br J Cancer 51:699–705CrossRefGoogle Scholar
  2. 2.
    Hinds MW (1978) Mesothelioma in the United States. Incidence in the 1970s. J Occup Med 20:469–471PubMedCrossRefGoogle Scholar
  3. 3.
    Silverberg E (1985) Cancer statistics. CA 35:19–35PubMedGoogle Scholar
  4. 4.
    Antman K, Corson JM (1985) Benign and malignant pleural mesothelioma. Clin Chest Med 6:127–140PubMedGoogle Scholar
  5. 5.
    Brenner J, Sordillio PP, Magill GB (1981) Malignant peritoneal mesothelioma: a review of 25 patients. Am J Gastroenterol 75:311–313PubMedGoogle Scholar
  6. 6.
    Rogers A, Leigh J, Berry G, Ferguson D, Mulder H, Ackad M (1993) Relationship between lung asbestos fiber type and concentration and relative risk of mesothelioma. Rev Respir Dis 148:25–31CrossRefGoogle Scholar
  7. 7.
    Chao C, Lund L, Zinn K, Aust A (1994) Iron mobilization from crocidolite asbestos by humanlung carcinoma cells. Biochem Biophys 314:384–391CrossRefGoogle Scholar
  8. 8.
    Hirvonen A, Pelin K, Tammilehto L, Karjalainen A, Mattson K, Linnainmaa K (1995) Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res 55:2981–2983PubMedGoogle Scholar
  9. 9.
    Oels HC, Harrison EG, Carr DT, Bernatz PE (1971) Diffuse malignant mesothelioma of the pleura: a review of 37 cases. Chest 60:564–570PubMedCrossRefGoogle Scholar
  10. 10.
    Said IW, Nash G, Lee M (1982) Immunoperoxidase localisation of keratin, proteins, carcinoembryonic antigen, and factor VIII in adenomatoid tumors: evidence for a mesothel derivation. Hum Pathol 13:1106–1108PubMedCrossRefGoogle Scholar
  11. 11.
    Warhol MJ, Hickey WF, Corson JM (1982) Malignant mesothelioma: ultra-structional distinction from adenocarcinoma. Am J Surg Pathol 6:307–314PubMedCrossRefGoogle Scholar
  12. 12.
    lones JSP, Lund C, Planteydt HT et al. (1985) Colour atlas of mesothelioma. MTP Press LimitedGoogle Scholar
  13. 13.
    Butchart EG, Ashcroft T, Barnsley WA, Holden MP (1976) Pleuropneumon-ectomy in the management of diffuse malignant mesothelioma of the pleura. Thorax 31:15–24PubMedCrossRefGoogle Scholar
  14. 14.
    Mattson K (1982) Natural history and clinical staging of malignant mesothelioma. Eur J Resp Dis 63:S 124Google Scholar
  15. 15.
    TNM-Klassifikation maligner Tumoren, 5. Auflage (1997) In: Wittekind Ch, Wagner G (Hrsg), Springer-VerlagGoogle Scholar
  16. 16.
    Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O’Sullivan B, Sobin LH, Yarbo JW (eds) (1997) AJCC-Cancer Staging Manual, 5th edn. Lippincott, PhiladelphiaGoogle Scholar
  17. 17.
    Meerbeeck JP (1994) Prognostic factors in malignant mesothelioma: where do we go from here. Eur J Resp Dis 7:1029–1031Google Scholar
  18. 18.
    Law MR, Gregor A, Hodson ME, Bloom HJG, Turner-Warwick M (1984) Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 39:255–259PubMedCrossRefGoogle Scholar
  19. 19.
    Alberts AS, Falkson G, Gaedhals L, Vorobiof DA, van der Merwe CA (1988) Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 6:527–535PubMedGoogle Scholar
  20. 20.
    Adams VI, Krishnan UK, Muhm JR, Jett JR, Ilstrup DM, Bernats PE (1986) Diffuse malignant mesothelioma of pleura. Cancer 58:1540–1551PubMedCrossRefGoogle Scholar
  21. 21.
    Antman K, Shemin R, Ryan L et al. (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients. The Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over 2 decades, 1965–1985. J Clin Oncol 6:147–153PubMedGoogle Scholar
  22. 22.
    Hillerdal G (1983) Malignant mesothelioma 1982: a review of 4710 published cases. Br J Dis Chest 77:321–343PubMedCrossRefGoogle Scholar
  23. 23.
    Ruffie P, Feld R, Minkin S et al. (1989) Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 7:1157–1168PubMedGoogle Scholar
  24. 24.
    van Gelder T, Damhuis RAM, Hoogsteden HC (1994) Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J 7:1035–1038PubMedGoogle Scholar
  25. 25.
    Grant DC, Seltzer SE, Antman K, Finnberg HJ, Koster K (1983) Computed tomography of malignant pleural mesothelioma. J Comput Assit Tomogr 7:626–632CrossRefGoogle Scholar
  26. 26.
    Maasilta P, Vehmas T, Kivisaari L, Tammilehto L, Mattson K (1991) Correlations between findings at computed tomography and at thorascopy/thoracotomy/ autopsy in pleural mesothelioma. Eur J Resp Dis 4:952–954Google Scholar
  27. 27.
    Sugarbaker DJ, Heher EC, Lee Th et al. (1991) Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 102:10–15PubMedGoogle Scholar
  28. 28.
    Sugarbaker DJ, Mentzer S, DeCamp M, Lynch TJ, Strauss GM (1993) Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest 103:377s-381sPubMedCrossRefGoogle Scholar
  29. 29.
    Sugarbaker DJ, Strauss GM, Lynch TJ et al. (1993) Node status has prognostic significance in the multimodality therapy of diffuse malignant mesothelioma. J Clin Oncol 11:1172–1178PubMedGoogle Scholar
  30. 30.
    Brenner J, Sordillio PP, Magill GB, Galbey RB (1982) Malignant mesothelioma of the pleura. Review of 123 patients. Cancer 49:2431–2435PubMedCrossRefGoogle Scholar
  31. 31.
    Krarup-Hansen A, Hansen HH (1991) Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 28:319–330PubMedCrossRefGoogle Scholar
  32. 32.
    Zeng L, Monnet I, Boutin C et al. (1993) In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines. Int J Cancer 55:515–520PubMedCrossRefGoogle Scholar
  33. 33.
    Chahinian AP, Norton L, Holland JF, Szrajer L, Hart RD (1984) Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma. Cancer Res 44:1688–1692PubMedGoogle Scholar
  34. 34.
    Chahinian AP, Antman K, Goutsou M et al. (1993) Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11:1559–1565PubMedGoogle Scholar
  35. 35.
    World Health Organisation (1979) WHO handbook for reporting results of cancer treatmentGoogle Scholar
  36. 36.
    Lee YL, Wesley RA (1981) Statistical contributions to phase II trials in cancer: interpretation, analysis and design. Semin Oncol 8:403–416PubMedGoogle Scholar
  37. 37.
    Magri MD, Foladore S, Veronesi A et al. (1992) Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. Ann Oncol 3:237–238PubMedGoogle Scholar
  38. 38.
    Solheim O, Saeter G, Finnanger A, Stenwig A (1992) High-dose methtrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65:956–960CrossRefGoogle Scholar
  39. 39.
    Pennucci MC, Ardizzoni A, Pronzato P et al. (1997) Combined cisplatin, doxorubicin and mitomycin for the treatment of advanced pleural mesothelioma. Cancer 79:1897–1902PubMedCrossRefGoogle Scholar
  40. 40.
    Meerbeeck JP, Baas P, Debruyne C et al. (1997) Gemcitabine in malignant pleural mesothelioma: A phase II study. Lung Cancer 18:Suppl. 1:17 (Abstract)CrossRefGoogle Scholar
  41. 41.
    Stewart DJ, Gertler SZ, Tomiak A, Shamji F, Goel R, Evans WK (1994) High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases. Lung Cancer 11:251–258PubMedCrossRefGoogle Scholar
  42. 42.
    Krarup-Hansen A (1994) Phase II trials of malignant mesothelioma: a commentary and update. Lung Cancer 11:305–308PubMedCrossRefGoogle Scholar
  43. 43.
    Middleton G, Verill M, Priest K, Spencher L, O’Brien M, Smith I (1997) Good symptom relief with palliative MVP (mitomycin C, vinblastine, cisplatin). Lung Cancer 18:22 (Abstract)CrossRefGoogle Scholar
  44. 44.
    Stewart DJ, Gertler SZ, Shamji F et al. (1997) High dose doxorubicin, cisplatin and tamoxifen vs mesothelioma. Lung Cancer 18:49 (Abstract)Google Scholar
  45. 45.
    Sørrensen PG, Bach F, Bork E, Hansen HH (1985) Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant mesothelioma. Cancer Treat Rep 69:1431–1432Google Scholar
  46. 46.
    Bautin C, Viallat JR, Astoul P (1990) Treatment of mesothelioma with interferon gamma and interleukin 2. Rev Pneumol Clin 46:211–215Google Scholar
  47. 47.
    Bautin C, Viallat JR, van Zandwijk N et al. (1991) Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 67:2033–2037CrossRefGoogle Scholar
  48. 48.
    von Hoff T, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE (1990) Phase-II evaluation of recombinant interferon-β (IFN-β ser) in patients with diffuse mesothelioma: a southwest oncology group study. J Interferon Res 10:531–534CrossRefGoogle Scholar
  49. 49.
    Robinson BWS, Manning LS, Bowman RV et al. (1993) The scientific basis for the immunotherapy of human malignant mesothelioma. Eur Respir Rev 3:195–198Google Scholar
  50. 50.
    Boutin C, Viallat JR, van Zandwijk N et al. (1991) Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 67:2033–2037PubMedCrossRefGoogle Scholar
  51. 51.
    Boutin C, Nussbaum E, Monnet I et al. (1994) Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 74:2460–2467PubMedCrossRefGoogle Scholar
  52. 52.
    Mulatero C, Penson R, Papamichael D, Gower N, Evans M Rudd R (1997) A phase II study of interleukin-2 in malignant pleural mesothelioma. Lung Cancer 18:18CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • A. Krarup-Hansen
  • H. H. Hansen

There are no affiliations available

Personalised recommendations